Hepatitis C—its prevalence in end-stage renal failure patients and clinical course after kidney transplantation

Transplantation

Volumn 55, Issue 2, 1993, Pages 273-276

  Stempel, Carlos A ^a   Lake, John ^b   Kuo, George ^c   Vincenti, Flavio ^a  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHRONIC HEPATITIS; DIALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; FEMALE; HEPATITIS ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMAN; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGE; PREVALENCE;

EID: 0027518586     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199302000-00008     Document Type: Article

References (26)

1. Bruguera M, Vidal L, Sanchez-Tapias JM, Costa J, Revert L, Rodes J. Incidence and features of liver disease in patients on chronic hemodialysis. J Clin Gastroenterol 1990; 12: 298.
2. Moyer LA, Alter MJ, Favero MS. Hemodialysis-associated hepa-titis B: revised recommendations for serologic screening. Semin Dial 1990; 3: 201.
3. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non­A, non-B viral hepatitis genome. Science 1989; 244: 359.
4. Bradley DW, Krawczynski K, Ebert JW, et al. Parenterally trans-mitted non-A, non-B hepatitis: virus-specific antibody response patterns in hepatitis C virus-infected chimpanzees. Gastroenter­ology 1990; 99:1054.
5. Mosley JW, Aach RD, Hollinger FB, et al. Non-A, non-B hepatitis and antibody to hepatitis C virus. JAMA 1990; 263: 77.
6. Esteban JI, Gonzalez A, Hernandez JM, et al. Evaluation of anti­bodies to hepatitis C virus in a study of transfusion-associated hepatitis. N Engl J Med 1990; 323:1107.
7. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1990; 321: 1494.
8. Sanchez-Tapias JM, Barrera JM, Costa J, et al. Hepatitis C virus infection in patients with nonalcoholic chronic liver disease. Ann Intern Med 1990; 112: 921.
9. Read AE, Donegan E, Lake J, et al. Hepatitis C in patients undergoing liver transplantation. Ann Intern Med 1991; 114:282.
10. Jeffers LJ, Perez GO, de Medina MD, et al. Hepatitis C infection in two urban hemodialysis units. Kidney Int 1990; 38: 320.
11. Zeldis JB, Depner TA, Kuramoto IK, Gish RG, Holland PV. The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Intern Med 1990; 112: 958.
12. Ware AJ, Luby JP, Hollinger B, et al. Etiology of liver disease in renal-transplant patients. Ann Intern Med 1979; 91: 364.
13. Parfrey PS, Farge D, Forbes RDC, Dandavino R, Kenick S, Gutt-mann RD. Chronic hepatitis in end-stage renal disease: compar­ison of HBsAg-negative and HBsAg-positive patients. Kidney Int 1985; 28: 959.
14. Kapra PM, Wall JH. Liquid chromatographic determination of cyclosporine in whole blood with the advanced automated sample processing unit. J Chromatogr 1987; 385: 305.
15. Kapra PM, Wall JH, Dimson P. Automated solid-phase extraction and liquid chromatography for assay of cyclosporine in whole blood. Clin Chem 1987; 33: 22-72.
16. Stevens CE, Taylor PE, Pindyck J, et al. Epidemiology of hepatitis C virus: a preliminary study in volunteer blood donors. JAMA 1990; 263: 49.
17. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506.
18. Weir R, Kirkman RL, Strom TB, Tilney NL. Liver disease in recipients of long-functioning renal allografts. Kidney Int 1985; 28: 839.
19. Debure A, Degos F, Pol S, et al. Liver diseases and hepatic com-plications in renal transplant patients. Adv Nephrol 1988; 17: 375.
20. Pirson Y, Alexandre GPJ, van Ypersele de Strihou C. Long-term effect of HBs antigenemia on patient survival after renal trans­plantation. N Engl J Med 1977; 296:194.
21. Parfrey PS, Forbes RDC, Hutchinson TA, Beaudoin JG, Dauphi-nee WD, Guttmann RD. The prevalence and progression of liver disease in renal transplant recipients: a histological study. Trans­plant Proc 1984; 16:1103.
22. Degos F, Degott C. Hepatitis in renal transplant recipients. J Hepatol 1989; 9:114.
23. Fernandez JA, Roth D, Burke G, Esquenazi V. Detection of anti-body to hepatitis C virus in renal allograft recipients and cadaver organ donors [Abstract]. J Am Soc Nephrol 1990; 1: 757.
24. LaQuaglia MP, Tolkoff-Rubin NE, Dienstag JL, et al. Impact of hepatitis on renal transplantation. Transplantation 1981; 32: 504.
25. Morales JM, Andres A, Campo C, et al. Clinical implications of the presence of antibody to hepatitis C positive after renal transplantation, Transplant Proc 1992; 24: 78
26. Stempel C, Lake J, Ferrell L, et al. Effect of cyclosporine on the clinical course of HBsAg-positive renal transplantation. Trans­plant Proc 1991: 23:1.